Bromocriptine use while Breastfeeding
Drugs containing Bromocriptine: Parlodel, Cycloset
Bromocriptine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Bromocriptine is usually not used during breastfeeding because it suppresses lactation and may increase the risk of maternal stroke and seizures. A low dose of 2.5 mg once daily has been used for 3 days to decrease overproduction of milk. The drug was undetectable in milk with this dosage and infants had no adverse reactions, but the safety of this use is not established. Case reports and series also exist of mothers treated with bromocriptine for amenorrhea-galactorrhea syndrome during pregnancy and lactation who successfully breastfed their infants.
Maternal Levels. In 14 women given bromocriptine 2.5 mg once daily, the drug was undetectable (<0.2 mcg/L) in breastmilk on consecutive 3 days, but the times with respect to the doses were not stated.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
No adverse effects were noticed in 14 breastfed infants of mothers who were given oral bromocriptine 2.5 mg once daily for 3 days beginning on day 5 postpartum to decrease overproduction of milk.
In a case series of 40 women with pituitary adenoma and hyperprolactinemia, 30 of the women took bromocriptine 2.5 or 5 mg daily during pregnancy. Thirty of the 40 women breastfed their infants, although it is not clear from the paper how many of the mothers continued to take bromocriptine during nursing. The authors reported that there were no abnormal findings in any of the breastfed infants. In an unstated number of infants who had their serum prolactin measured, it took 6 to 9 weeks for their elevated serum prolactin levels to return to baseline values.
A mother who was receiving bromocriptine (dosage not stated) for hyperprolactinemia from a pituitary macroadenoma breastfed her infant partially for 2 days and then exclusively from the third day onward (duration not sated). The infant had no observable side effects. She had regained her birthweight on day 10 and had gained weight adequately at 5 months.
Effects on Lactation and Breastmilk
With doses of 2.5 mg 1 to 3 times daily (usually twice daily), there is a marked reduction in serum prolactin, no increase in serum prolactin following nipple stimulation and little or no breast engorgement. Treatment is usually given for 14 days. A meta-analysis of published studies found evidence that bromocriptine is more effective than placebo for lactation suppression during the first week postpartum, but evidence is insufficient to comment on the acceptability of such therapy. Rebound lactation after cessation of therapy may be controlled with a dose of 2.5 mg once daily for 1 additional week.
Bromocriptine also prevents puerperal fever caused by either breast engorgement or infection among women who do not nurse their newborn infants. The indication of postpartum breast engorgement was removed in the United States in 1994 because of serious maternal toxicity, including stroke (some fatal), convulsions, myocardial infarction (some fatal) and severe hypertension. One study found that seizure risk was decreased in the early puerperium, but increased slightly later. Cerebral angiopathy, stroke and seizures continue to be reported from countries where bromocriptine is still used to suppress lactation.
An early double-blind study in 60 women who were less than 24 hours postpartum found bromocriptine to be as effective as diethylstilbestrol in suppressing postpartum lactation. Bromocriptine was given in a dosage of 5 mg twice daily for 6 days followed by 5 mg three times daily for 3 days. Diethylstilbestrol dosage was 20 mg twice daily for 3 days, followed by 10 mg twice daily for 3 days, then 10 mg daily for 3 days.
Hyperprolactinemia and galactorrhea have been reported occasionally after withdrawal of long-term therapy with high doses (5 to 10 mg 3 times daily) of bromocriptine for treatment of parkinsonism.
In women given bromocriptine immediately postpartum, the composition of milk is altered from the milk of normal lactation. Most protein constituents (e.g., total protein, albumin, alpha-lactalbumin, lactoferrin, IgA and IgG) appear in higher concentrations than normal, similar to those of colostrum. Lactose levels are suppressed.
A study in 14 women who were overproducing milk on day 3 postpartum found that oral bromocriptine 2.5 mg once daily for 3 days reduced serum prolactin to subnormal levels, but rebounded to control levels by 36 hours after the last dose. In contrast, the milk yield decreased by 25% from baseline and the decrease persisted for at least 12 days afer the last dose.
A woman who was treated with bromocriptine 5 mg daily for the amenorrhea-galactorrhea syndrome during pregnancy continued taking the drug in the same dosage after delivery and successfully breastfed her infant.
In a case series of 40 women with pituitary adenoma and hyperprolactinemia, 30 of the women took bromocriptine 2.5 or 5 mg daily during pregnancy. Thirty of the 40 women were able to breastfeed successfully, although it is not clear from the paper how many of the mothers continued to take bromocriptine during nursing.
A mother who was receiving bromocriptine (dosage not stated) for hyperprolactinemia from a pituitary macroadenoma successfully breastfed her infant partially for 2 days and exclusively from the third day postpartum onward (total duration not stated). She received support from professionals and a relative who was nursing.
Alternate Drugs to Consider
(Lactation suppression, hyperprolactinemia) Cabergoline
1. Peters F, Geisthovel F, Breckwoldt M. Serum prolactin levels in women with excessive milk production. Normalization by transitory prolactin inhibition. Acta Endocrinol (Copenh). 1985;109:463-6. PMID: 3898690
2. Cheng W, Zhang Z. [Management of pituitary adenoma in pregnancy]. Zhonghua Fu Chan Ke Za Zhi. 1996;31:537-9. PMID: 9275425
3. Verma S, Shah D, Faridi MM. Breastfeeding a baby with mother on bromocripine. Indian J Pediatr. 2006;73:435-6. PMID: 16741332
4. Oladapo OT, Fawole B. Treatments for suppression of lactation. Cochrane Database Syst Rev. 2009;CD005937. PMID: 19160258
5. Rolland R. Use of bromocriptine in the inhibition of puerperal lactation. Drugs. 1979;17:326-36. PMID: 378648
6. Almeida Jr OD, Kitay DZ. Lactation suppression and puerperal fever. Am J Obstet Gynecol. 1986;154:940-1. PMID: 3963089
7. US Food and Drug Administration. FDA moves to end use of bromocriptine for postpartum breast engorgement. FDA Talk Paper T94-37. 1994.
8. Rothman KJ, Funch DP, Dreyer NA. Bromocriptine and puerperal seizures. Epidemiology. 1990;1:232-8. PMID: 2081258
9. Comabella M, Alvarez-Sabin J, Rovira A et al. Bromocriptine and postpartum cerebral angiopathy: a causal relationship? Neurology. 1996;46:1754-6. PMID: 8649587
10. Burckard E, Patrigeon RG, Felten D et al. [Convulsions due to a postpartum cerebral angiopathy associated with the administration of bromocriptine]. Ann Fr Anesth Reanim. 2003;22:46-9. PMID: 12738020
11. Barroso B, Bigou P, Martin K et al. [Reversible postpartum cerebral angiopathy associated with bromocriptine therapy]. Rev Neurol (Paris). 2004;160:1191-3. PMID: 15602366
12. Varga L, Lutterbeck PM, Pryor JS et al. Suppression of puerperal lactation with an ergot alkaloid: a double-blind study. Br Med J. 1972;2:743-4. PMID: 4556543
13. Pentland B, Sawers JSA. Galactorrhoea after withdrawal of bromocriptine. Br Med J. 1980;281:716. Letter. PMID: 7191752
14. Kulski JK, Hartmann PE, Martin JD et al. Effects of bromocriptine mesylate on the composition of the mammary secretion in non-breast-feeding women. Obstet Gynecol. 1978;52:38-42. PMID: 355958
15. Canales ES, Garcia IC, Ruiz JE et al. Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil Steril. 1981;36:524-6. PMID: 7286276
CAS Registry Number
LactMed Record Number
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.